Boehringer Ingelheim's Ofev nabs FDA nod for expanded use in rare lung disease

Boehringer Ingelheim's Ofev can now treat between 18% and 32% of patients with an interstitial lung disease. (Boehringer)

Boehringer Ingelheim cast a wide net with its clinical program for pulmonary fibrosis med Ofev, hoping to carve out a sales niche in a huge range of ultrarare lung diseases. Already sporting an FDA nod in one subclass, Ofev can now target an even larger patient pool with its newest approval.

The FDA on Monday approved Ofev to treat patients with range of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, Boehringer said in a release. 

Ofev's newest approval covers between 18% and 32% of total patients with an ILD, a category that includes around 200 diseases that can lead to irreversible scarring of lung tissue, Boehringer said.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Ofev already sports FDA approvals to treat pulmonary fibrosis and systemic sclerosis-associated ILD (SSc-ILD), another subclass of ILDs that is believed to affect about 50,000 Americans each year. 

RELATED: Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases

The FDA based its review on data from Boehringer's phase 3 Inbuild study, which showed Ofev significantly slowed the rate of lung function decline in patients with a range of progressive, non-IPF ILDs by 57% over placebo after 52 weeks.

Inbuild on the whole studied Ofev in a wide range of ILDs, including those with a progressive phenotype and SSc-ILD, the drugmaker said, an indication where Ofev notched an FDA nod in September. That approval––the first of its kind––followed a phase 3 clinical trial, dubbed Senscis, in which Ofev beat out placebo in terms of slowing the decline of forced vital capacity—a measure of lung function—in 576 patients treated for a minimum of 52 weeks and maximum of 100 weeks. 

Ofev received its initial approval in idiopathic pulmonary fibrosis back in 2014.

Suggested Articles

The U.K. became the first Western country to authorize a COVID vaccine, making the Pfizer/BioNTech shot the first mRNA vaccine for widespread use.

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.